Chordia Therapeutics Inc.
TTSE:190ATotal Valuation
JPYAs of February 28, 2026, Chordia Therapeutics Inc. carries a market capitalization of 12.31B, placing it among publicly traded companies globally. Its enterprise value stands at 9.87B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 12.31B |
| Enterprise Value | 9.87B |
Important Dates
Chordia Therapeutics Inc.'s next confirmed earnings release is scheduled for January 20, 2027.
| Earnings Date | 1/20/2027 |
Share Statistics
As of February 28, 2026, Chordia Therapeutics Inc. has 73.73M shares outstanding.
| Shares Outstanding | 73.73M |
Valuation Ratios
These figures are as of February 28, 2026.
| PB Ratio | 5.32 |
| P/TBV Ratio | 5.32 |
Financial Position
As of February 28, 2026, Chordia Therapeutics Inc. maintains a current ratio of 12.67, meaning it holds 12.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 12.67 |
| Quick Ratio | 12.41 |
Financial Efficiency
These figures cover the twelve months ended February 28, 2026.
| Employee Count | 20.50 |
Stock Price Statistics
JPYAs of the close on October 22, 2026, Chordia Therapeutics Inc.'s stock has declined approximately 57.02% over the past 52 weeks. The 50-day moving average sits at 68.82, while the 200-day moving average is 101.28.
| 52-Week Price Change | -57.02% |
| 50-Day Moving Average | 68.82 |
| 200-Day Moving Average | 101.28 |
Balance Sheet
JPYThese figures are as of February 28, 2026. Total book value stands at 2.32B, with working capital of 2.30B providing operational flexibility.
| Cash & Cash Equivalents | 2.45B |
| Net Debt | -2.45B |
| Equity (Book Value) | 2.32B |
| Book Value Per Share | 31.40 |
| Working Capital | 2.30B |